



FY 2023 Investor Presentation

As of February 2024


DISCLAIMER

Disclaimer and important information in relation to this presentation

This presentation is for general use only and is not necessarily comprehensive as it has not been independently verified, nor is it considered or constitutes part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or solicitation to buy or subscribe for any Securities in KSA, and does not constitute an offer, invitation or recommendation in connection with the purchase, ownership or sale of any securities of the HMG. The Group does not warranty, express or implied, regarding the accuracy, completeness, or correctness of the information or opinions contained in this presentation, and no person or legal entity should rely for any purpose on the information contained in this presentation.

This presentation may include statements that are or may be considered "forward-looking statements" regarding the Company's financial position, results of operations and business, and certain of the HMG's plans, expectations, assumptions, and objectives, which are for general update only and do not constitute or constitute an invitation or inducement to engage in any investment activity, It does not constitute an offer or invitation to buy or subscribe to any securities in the KSA and does not constitute an offer, invitation or recommendation in connection with the purchase, ownership or sale of any securities of HMG. The information contained in this presentation, including but not limited to forward-looking statements, is current as of the date of this presentation and is not intended to provide any assurances about future outcomes. HMG expressly releases itself from any obligation or undertaking to publish any updates or revisions to this presentation, including financial statements or forward-looking statements, that may arise as a result of the emergence of new information, the occurrence of future events or otherwise, unless required by applicable laws and regulations. This presentation should not be construed by anyone as financial, tax, or investment advice. Neither HMG nor any of its directors or employees shall be liable for any direct or indirect loss or damage that any person may incur as a result of relying on the forward-looking statements.

PRESENTING TEAM














KEY FINANCIAL HIGHLIGHTS: FY 2023




















BALANCE SHEET HIGHLIGHT


FY 2022 **Total assets** SAR 12.58 billion Cash, time deposit & bank 20.58% 21.83% balances Accounts 5.89% receivable 3.90% **Inventories** 1 44% 30.90% Other current assets 66.94% Non-current 48.52% assets Liabilities Assets & Equity




















LOW LEVERAGE LEVELS


Total liabilities and equity


SAR million

















TOTAL CASH DIVIDENDS FOR SHAREHOLDERS

Declared dividends

Q4 2023	SAR 1.15 per share	SR 402.5mn 76.7% Payout
Q3 2023	SAR 1.17 per share	SR 409.5mn 75.2% Payout
Q2 2023	SAR 1.00 per share	SR 350.0mn 71.9% Payout
Q1 2023	SAR 1.00 per share	SR 350.0mn 71.5% Payout
Q4 2022	SAR 0.93 per share	SR 325.5mn 73.7% Payout
Q3 2022	SAR 0.86 per share	SR 301.0mn 71.6% Payout
Q2 2022	SAR 0.86 per share	SR 301.0mn 75.6% Payout
Q1 2022	SAR 0.83 per share	SR 290.5mn 74.4% Payout
Q4 2021	SAR 0.70 per share SR 24	5.0mn 63.9% Payout
Q3 2021	SAR 0.70 per share SR 24	5.0mn 70.3% Payout
Q2 2021	SAR 0.70 per share SR 24	5.0mn 75.3% Payout
Q1 2021	SAR 0.70 per share SR 24	5.0mn 76.8% Payout
Q4 2020	SAR 0.60 per share SR 210.0mm	66.1% Payout
Q3 2020	SAR 0.60 per share SR 210.0mm	70.3% Payout
Q2 2020	SAR 0.40 per share SR 140.0mn 72.8% Payo	ut
Q1 2020	SAR 0.50 per share SR 175.0mn 71.0	% Payout

Declared Cash dividends / Q4 2023

Total distributed dividends	SAR 402.50 million
% of capital	11.50% (equivalent to SAR 1.15 per share)
Eligibility date	Close of trading on Wednesday, 21st February 2024
Date of distribution	Monday, 4 th March 2024



Dividend declared (SAR million)



HIGHLIGHTS: 2023 PATIENT OVERVIEW


Patient overview




Bed occupancy - overall



Revenue by type



Bed occupancy - ICU





PROJECTS UPDATE

Solidifying our market leadership through a robust expansion plans and progressing our projects


South-West Jeddah Hospital

2024 Expected

completion


Excavation MoH Construction license

W North Riyadh Hospital



Design Excavation MoH Construction Land license


Expansion of Qassim Hospital



license







50%

Design

Land

Ownership

PROJECTS UPDATE

Solidifying our market leadership through a robust expansion plans and progressing our projects



2024

Expected

completion

(New Takhassusi Expansion)

Maternity and Pediatric Hospital

100% Ownership

2024 Expected completion North Jeddah Hospital





2024 Expected completion



Design Land

100%

Ownership

MoH license Excavation

Construction

Land

Design

MoH license

Excavation

Construction

Land


Design

MoH license

Excavation Construction







PROJECTS UPDATE


Solidifying our market leadership through a robust expansion plans and progressing our projects


Sehat Al Kharj Hospital


Hamra Hospital


Tabuk Hospital

Madinah Hospital



















Key Highlights

- Launched three medical centers in Riyadh: Digital City, Narjis and Ghadeer.
- Announced to establish the 140 beds Hospital in Tabuk city at an estimate total cost of SAR 420 million.
- Signed conditional investment agreement with Royal Commission for Jubail and Yanbu to construct and operate a hospital in Jubail Industrial City.
- Signed strategic partnership with King Abdullah Economy city (KAEC) to establish medical center.
- First private healthcare provider in the Kingdom to use AI technology to detect breast cancer.
- Signed cooperation agreement with University College London Global Business School of Health (UCL GBSH) to empower our leaders with modern skills crucial for effective healthcare management, which include tailored educational and training programs for the Group's personnel.
- Signed agreements with multiple national and international universities to develop and qualify national human resources in the healthcare sector.

HMG Mobile Application

11%

Booked Appointments 40% +4.05 m appointments


Habib Live Care

→ 117%

+290 k transactions

E-Pharmacy 144% +197 k transactions

Home Health care +22 k transactions



Annual Growth

RECOGNITIONS & ACCREDITATIONS

HMG continues to receive recognitions and accreditations from organizations around the world in recognition of our service quality and standards.





































MEDICAL EXCELLENCE

Creating the medical practitioners of the future and promoting health and well-being



Research Center

- 4 Journals issued
- 20+ Research papers published in Dr.
 Sulaiman Al Habib Medical Journal
- 130+ Research proposals submission to IRB



Continuous Medical Education

230+ Activities 500+ Hours

460+ Speakers 9,400+ Participant



Undergraduate Program

2,900+ Undergraduate and interns

24 Governmental and Private Universities



CPR

980+ Courses

6,200+ Participant



Postgraduate Program

30+

Residency & Fellowship program in Riyadh and Khobar accredited by Saudi Commission for Health Specialties (SCFHS)

200+

Total participants in residency and fellowship program


380

Enrolled in Riyadh and Khobar across 5 SCFHS- accredited diploma

OUR PEOPLE

Continued to attract and retain top talent in the Kingdom

17,500+ Employees	58% female	+39% Saudization
LITIPIOYEES	42% male Staff ratio	Saudization
80+	120+ recruiting	
Nationalities	offices across the globe	
In-house H	MG training for our pe	eople:
2,100 +	trainings conducted	
5,200 +	employees participat	ed
8.100 +	training hours	



ESG & SUSTAINABILITY

The Group's ESG structures and targets aim to maximize the benefits we deliver in terms of patient health, the broader contexts of social and human development, and responsible environmental stewardship

ESG Roadmap

HMG is undertaking a four-phase exercise to start integrating ESG into our business practices and to measure and report on our ESG performance.



ESG benchmarking: Traffic light assessment of existing key problem areas.



Materiality assessment: Stakeholder mapping and materiality assessment



Formulating strategy: Developed a Sustainability Strategy to serve as a Vision document. Established a cross-functional committee to help operationalize the ESG strategy



Implementation and Reporting: Preparation of all the necessary requirements/documentation to disclose information in accordance with GRI and SASB reporting standards. On track to deliver HMG's first ESG standalone report in 2024

CSR Activities

- Celebrated World Blood Donor Day in partnership with National Association for the Blind "Kafeef" and launched a pioneering Braille blood donation form.
- Supported a clothing donation campaign for Ehtwaa, one of Saudi Arabia's most respected non-profit organizations.
- Sponsored the fifth Sports Championship for specially-abled people.
- Signed a cooperation agreement with the Saudi Federation of Sports Medicine in the fields of training and education.
- Organized the Irish Fellowship Exam in Clinical Medicine after its success in Obstetrics, Gynecology, and Internal Medicine.
- Premium medical sponsor of Riyadh Season for the fourth consecutive time.
- Medical sponsor for Formula 1 Saudi Arabian Grand Prix, FIFA Club World Cup, Saudi Cup for Equestrian and Horse Racing, and Saudi Games.
- Conducted over 60 events, awareness and wellness campaigns in different locations in Dubai.



SUMMARY: BALANCE SHEET

As of 31 December 2023

SAR million	FY 2023	FY 2022
Current Assets	4,137.83	4,160.48
Investment in Associates	197.59	187.00
Investments in equity instruments – Sukuk	300.00	300.00
Property and Equipment	11,162.62	7,936.64
Total Assets	15,798.04	12,584.12
Current Liabilities	3,299.16	2,590.31
Non-Current Liabilities	5,732.63	3,888.14
Equity attributable to equity holders of the parent	6,485.49	5,878.70
Non-controlling interests	280.76	226.97
Total Liabilities and Equity	15,798.04	12,584.12

SUMMARY: INCOME STATEMENT

As of 31 December 2023

SAR million	FY 2023	FY 2022	Change %
Revenue	9,508.44	8,310.74	14.41%
Cost of revenue	(6,238.39)	(5,562.60)	12.15%
Gross profit	3,270.05	2,748.14	18.99%
Selling and marketing expenses	(402.70)	(324.78)	23.99%
General and administrative expenses	(771.70)	(722.87)	6.76%
Operating income	2,095.65	1,700.49	23.24%
Other income	122.27	125.92	38.17%
Share of income of associates	22.18	19.61	(2.90%)
Finance costs	(70.11)	(49.36)	42.04%
EBT and before non-controlling interests	2,169.99	1,796.66	20.78%
Zakat	(68.52)	(107.71)	(36.38%)
Income before non-controlling interests	2,101.47	1,688.95	24.42%
Non-controlling interests	(55.46)	(38.20)	45.18%
Net income (Attributable to Equity holders of the Parent)	2,046.01	1,650.75	23.94%

SUMMARY: CASH FLOW STATEMENT

As of 31 December 2023

SAR million	FY 2023	FY 2022
Net cash from operating activities	3,244.15	2,843.68
Net cash used in investing activities	(3,486.63)	(1,939.40)
Net cash from (used in) financing activities	115.87	(801.12)
Cash and cash equivalents at the beginning of the year	2,746.99	2,643.83
Cash and cash equivalents at the end of the year	2,620.38	2,746.99



A FULLY INTEGRATED HEALTHCARE SERVICES PROVIDER



Dr. Sulaiman Al Habib Medical Services Group Company (HMG) is a diversified healthcare leader in the Middle East, recognized for comprehensive healthcare services, forward-thinking innovation and the superior patient experience in the region.

OUR VISION



To be the most trusted healthcare provider in medical excellence and patient experience globally.

OUR MISSION



To develop and operate state-of-theart medical facilities and provide innovative healthcare services to create value for people.



25 **Medical Facilities**



24 Pharmacies



3,900+ Physicians






Upcoming Projects:

8 Hospitals

2 Medical Centers



60+ Sub-specialties



1,900+ Beds



17,500+ Staff

WHERE WE OPERATE

With total built-up area of 689,000+ m2, HMG owns most of its hospital properties Tabuk Hospital Neom KINGDOM OF Kingdom of SAUDI ARABIA Hospital under construction Bahrain Dammam (x) Qassim ** Medical Center Khobar Madinah Dubai 👺 Medical Center under construction Riyadh KAEC UAE Operated contract Kharj Jeddah

OUR STRATEGY

Our well-defined growth strategy enhanced by our core values

Our Value



Integrity & Trust



Attract & Invest in the best People



Excellence and Quality



Care for Patients and Communities



One Team



Innovate, Simplify & Always improve



Safety & Security



Accountability



Think Big & Act Fast

Our Pillar

Strengthening our core

Drivers: Human capital, cutting-edge technology and

operational efficiency

Outcomes: Patient centric healthcare

Expanding our reach

Drivers: Central region, other major Saudi cities, wider

GCC

Outcomes: Organic growth while considering inorganic

opportunities

Broadening our services

Drivers: Design and develop, operate and manage, digital

healthcare solutions

Outcomes: Creation of new business lines

Our Priorities



Provide integrated healthcare services



Maintain position as leading brand in the market



Meet demand in growing sectors and diversify income sources



Increase operational efficiency



Expand to new locations



Attract and retain highly qualified physicians, healthcare practitioners & administrative staff

KEY MESSAGE

Strategic pillars underpin our drive to deliver best-in-class healthcare services

* Best-in-class

- Regional integrated healthcare provider with 25+ year track record
- Resilient revenues and stable gross margins supported by economies of scale, strong cash flow management and healthy balance sheet
- Defined strategy to strengthen core, expand reach and broadening the services



Catalysts for value creation

- Technology: Pioneer in healthcare technology, award-winning hospital information system (HIS) & other 19 Technology Products
- Robust expansion plan: 8 new Hospitals and 2 new Medical Centers under construction and expansion.
- Supporting medical community: Heavily invested in creating an enabling environment conductive to research, innovation and scientific creativity in the Kingdom, in line with the objectives of the 2030 Vision




Efficiency drivers

- Efficient cash conversion cycle: shortest CCC in the industry, proactive collection process
- Cost efficiency: economies of scale and cost efficiency on a growing patient volume base
- Technology to drive operational efficiency: best in class HIS, patients and physicians apps and rapidly growing business solutions including special focus on automation of services

BUSINESS STRUCTURE

A fully integrated healthcare services provider








Outpatient pharmacies as part of the hospitals

24 Pharmacies in Saudi Arabia and Dubai

E- pharmacy services



Cloud Solutions	Providing leading-edge technological solutions to boost healthcare quality and patient experience
MD Lab	Offering advanced laboratory testing services
Home Healthcare	Delivers convenience of care at comfort of home
FLOW Medical Solutions	A 360-degree integrated healthcare technology and technical solutions provider managing medical equipment
Taswyat	Provides complete end-to-end healthcare Revenue Cycle Management (RCM) services

BUSINESS MODEL

Through our vertically integrated business model, we are committed to create sustainable value for our stakeholders

OUR KEY STRENGTHS

Cutting-edge Technology

Leading Brand in Prime Locations

Strategic Relationships and In-house Expertise

Experienced Management and Qualified Health Practitioners

Reputation for Medical Excellence

WHAT WE DO



Facilities and services



Digital healthcare solutions



Design, develop and operate

HOW WE MAXIMISE VALUE

Patient-centric approach


Continuum of care

Value engineering

Sound risk management

Adapting to change

OUR STORY



MEDICAL EXCELLENCE


Medical Operation Strategic Pillars

Patient Safety

HMG artificial heart and lung program is one of many sophisticated services that increases our confidence in the advanced quality care we provide to our patients.

Patient Experience

Introducing new services, such as fast track clinic for patients who need intravenous medications, has received wide acclaim from our patients



Performance & Efficiency

HMG significantly reduced the admission waiting time for our patients and ensured their timely discharge from our hospitals.

Standardization

HMG works tirelessly to ensure that all services provided by HMG are standardized by meeting widely acceptable international standards.

Innovation

HMG remains focused on providing seamless, integrated medical experiences for our patients through procuring and implementing cutting edge innovative technology to provide optimum quality of care.

PIONEER IN HEALTHCARE TECHNOLOGY

Better medical outcomes, exceptional patient experience, and advanced operational practices

Tele-medicine



Tele-Cardiology (Nabad 24 program)

Designed to treat heart attacks remotely

Tele-ICU Center

World record-breaking, working 24/7, provides continuous real-time monitoring of ICUs

Tele-stroke

First facility in the region to use tele-medicine technology to rapidly diagnose and react to stroke remotely

Tele EEG

The 1st tele EEG center in the Middle East; utilizes latest cutting-edge technology under supervision of highly trained and experienced epileptologist.

Tele-radiology

Improving efficiency and quality of care as well as central reporting 24/7

HIS (VIDA)




Pioneer in healthcare technology, award-winning hospital information system (HIS) marked under VIDA brand.

- VIDA is first-of-its-kind electronic portal that helps in storing and managing medical procedures, diagnostics, and analysis.
- Integrates healthcare provision stages in a paperless environment.
- Web-Based (Cloud Based)
- Built using the industry's best practices and healthcare standards such as HL 7, ICD 10, CPT.
- Achieved HIMSS stage 7 accreditation in all HMG's hospital in KSA.
- Implemented VIDA in 40+ MoH facilities

Developing cutting edge technology







14 Digital healthcare

19 Products

25+ Clients

35+ International partnerships

70+ University student internships

15+ Years of experience in deploying technology solutions in healthcare domain

DIVERSE BOARD OF **DIRECTORS**Our success is driven by our people

3 NON-EXECUTIVES



Dr. Sulaiman Al Habib Chairman



Mr. Mazen Al Rumaih Vice Chairman



2 EXECUTIVES

Mr. Hesham Al Habib **Board Member and Chief** Business Development & Strategy

Mr. Faisal Al Nassar

Board Member,

CEO





Mr. Obaid Al Rasheed **Board Member**



Dr. Abdulrahman Al Taraigi **Board Member**



Mr. Rasheed Al Rasheed **Board Member**



Eng. Saleh Al Habib **Board Member**

HMG's COMMITTEES

Our success is driven by our people

AUDIT COMMITTEE



Dr. Abdulrahman Al TuraigiChairman



Mr. Rasheed Al Rasheed Member



Mr. Turki Al Luhaid Member

NOMINATION & RENUMERATION COMMITTEE



Mr. Obaid Al Rasheed Chairman



Eng. Saleh Al Habib Member



Mr. Ahmad Al Sudais Member

EXECUTIVE COMMITTEE



Mr. Mazen Al Rumaih Chairman



Eng. Saleh Al Habib Member



Mr. Faisal Al Nassar Member



Mr. Hesham Al Habib Member

PATIENT SAFETY & QUALITY OF CARE COMMITTEE



Prof. Mahmoud Al Ahwal Chairman



Dr. Abdulelah Al Hawsawi Member



Prof. Abdullah Al Herbish Member

EXPERIENCED SENIOR MANAGEMENT

Highly experienced, high caliber management



Mr. Faisal Al Nassar CEO

CORE FUNCTIONS



Dr. Abdulwahab
Al Abdulwahab
Chief Operating Officer



Prof. Awad Al Omari Chief Medical Officer & CEO of Critical Care Co.



Prof. Abdullah Al Herbish Senior Vice President, Physicians Affairs



Prof. Sulaiman Al Majed Senior Vice President, Medical Affairs

CORPORATE FUNCTIONS



Mr. Hesham Al Habib
Chief Business
Development & Strategy

Mr. Saud Al Arifi

General Counsel of

Mr. Mustapha Al Aoui

Vice President,

Vice President,

Supply Chain

the Group



Ms. Emmeline
Roodenburg
Vice President,
Strategy



Mr. Badr Al Rowaili Vice President, Human Resources



Eng. Abdullah
Al Sudais
CEO of Primary
Healthcare Co.



INDEPENDENT FUNCTIONS

Dr. Riyad Al Atiqi General Director Pharmacy Company



Eng. Abdulelah
Al Mayman
CEO of Cloud
Solutions



Eng. Feras
Al Humayed
CEO of FLOW
Medical Solutions



Mr. Riyadh Bajodah CEO of Taswyat Co.



Mr. Vimal
Subramanian
Head of Internal
Audit

Thank you

Dr. Sulaiman Al Habib Medical Services Group

Tel: +966 11 525 9999 Ext# 4919

Mobile: +966 50 338 2785

Email: investor.relations@drsulaimanalhabib.com

Website: www.hmg.com